Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study.
Victoria HamillStanley WongJennifer BenselinMel KrajdenPeter C HayesDavid MutimerAmanda YuJohn F DillonWilliam GelsonHector A Velásquez GarcíaAlan YeungPhilip JohnsonStephen T BarclayMaria AlvarezHidenori ToyodaKosh AgarwalAndrew FraserSofia BartlettMark AldersleyAndy BathgateMawuena BinkaPaul RichardsonJoanne R MorlingStephen D RyderDouglas MacDonaldSharon HutchinsonEleanor BarnesIndra Neil GuhaWilliam L IrvingNaveed Z JanjuaHamish InnesPublished in: BMJ (Clinical research ed.) (2023)
Mortality rates among people successfully treated for hepatitis C in the era of interferon-free, direct acting antivirals are high compared with the general population. Drug and liver related causes of death were the main drivers of excess mortality. These findings highlight the need for continued support and follow-up after successful treatment for hepatitis C to maximise the impact of direct acting antivirals.